Cynata Therapeutics Cash Per Share vs. Number Of Employees
| CYYNF Stock | USD 0.19 0.00 0.00% |
For Cynata Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Cynata Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Cynata Therapeutics Limited utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Cynata Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Cynata Therapeutics Limited over time as well as its relative position and ranking within its peers.
Cynata |
Cynata Therapeutics Number Of Employees vs. Cash Per Share Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Cynata Therapeutics's current stock value. Our valuation model uses many indicators to compare Cynata Therapeutics value to that of its competitors to determine the firm's financial worth. Cynata Therapeutics Limited is number one stock in cash per share category among its peers. It also is number one stock in number of employees category among its peers creating about 52.63 of Number Of Employees per Cash Per Share. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cynata Therapeutics' earnings, one of the primary drivers of an investment's value.Cynata Number Of Employees vs. Cash Per Share
Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Cynata Therapeutics |
| = | 0.19 X |
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
Number of Employees shows the total number of permanent full time and part time employees working for a given company and processed through its payroll.
Cynata Therapeutics |
| = | 10 |
Employee typically refers to an individual working under a contract of employment, whether oral or written, express or implied, and has recognized his or her rights and duties. Most officers of corporations are included as employees and contractors are generally excluded.
Cynata Number Of Employees vs Competition
Cynata Therapeutics Limited is number one stock in number of employees category among its peers. The total workforce of Biotechnology industry is currently estimated at about 450. Cynata Therapeutics holds roughly 10.0 in number of employees claiming about 2.22% of stocks in Biotechnology industry.
Cynata Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Cynata Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Cynata Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Cynata Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Cynata Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. Cynata Therapeutics Limited was founded in 2011 and is based in Cremorne, Australia. Cynata Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange.
Cynata Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Cynata Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Cynata Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Cynata Therapeutics' important profitability drivers and their relationship over time.
Use Cynata Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cynata Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cynata Therapeutics will appreciate offsetting losses from the drop in the long position's value.Cynata Therapeutics Pair Trading
Cynata Therapeutics Limited Pair Trading Analysis
The ability to find closely correlated positions to Cynata Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cynata Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cynata Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cynata Therapeutics Limited to buy it.
The correlation of Cynata Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cynata Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cynata Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cynata Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Cynata Therapeutics position
In addition to having Cynata Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Russia On Wall Street Thematic Idea Now
Russia On Wall Street
Cross-sector and cross-instrument bundle of publicly traded Russian entities that are expected to be listed on USA exchanges or over the counter. The Russia On Wall Street theme has 23 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Russia On Wall Street Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Cynata Pink Sheet
To fully project Cynata Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Cynata Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Cynata Therapeutics' income statement, its balance sheet, and the statement of cash flows.